Taysha Gene Therapies Receives 'Moderate Buy' Rating from Analysts

Analysts see potential upside for the gene therapy company despite ongoing development risks and cash burn

Mar. 21, 2026 at 8:58am

Got story updates? Submit your updates here. ›

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received a 'Moderate Buy' consensus rating from 12 research firms covering the stock. While one analyst has a 'Sell' recommendation, ten have issued 'Buy' ratings and one has a 'Strong Buy' on the company.

Why it matters

Taysha Gene Therapies is a clinical-stage biotech focused on developing gene therapies for rare central nervous system disorders. Analyst sentiment and ratings can impact investor perception and the stock price, especially for a pre-revenue company like Taysha relying on clinical milestones.

The details

The average 12-month price target from the analysts covering Taysha is $11.09. Several firms have issued positive commentary, with Needham raising its price target to $12 and reiterating a 'Buy' rating. The company also recently reported Q4 2025 results that topped expectations on both earnings and revenue.

  • Taysha Gene Therapies completed its IPO in May 2021.
  • The company reported Q4 2025 earnings on March 19, 2026.

The players

Taysha Gene Therapies, Inc.

A clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system.

Needham & Company LLC

An investment banking and asset management firm that raised its price target on Taysha to $12 and maintained a 'Buy' rating.

Chardan Capital

An investment bank that reaffirmed a $12 'Buy' target on Taysha Gene Therapies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

The company is advancing enrollment in a pivotal trial for its lead program TSHA-102, with plans to complete dosing in Q2 2026 and submit a Biologics License Application (BLA) later that year.

The takeaway

While Taysha Gene Therapies remains unprofitable with significant development risks, the positive analyst sentiment and upcoming clinical catalysts suggest the company's gene therapy pipeline holds promise if it can achieve regulatory milestones.